Medikine, Inc.

Affymax Technologies, N.v.

Xenoport, Inc.

Glaxo Group Limited

Glaxo Wellcome Inc.

Smithkline Beecham Corporation

Affymax, Inc.

Glaxosmithkline LLC

Steven E Cwirla

William J Dower

Ronald W Barrett

Michael C Needels

Alice V Bakker

Peter J Schatz

Christopher R Wagstrom

Christian M Gates

David J Duffin

Nicholas C Wrighton

Qun Yin

Larry C Mattheakis

Christine L Martens

Richard Wayne Hendren

Palaniappan Balasubramanian

Surekha Podduturi

Sherril S Haselden

Mark A Gallop

Kerry J Koller

Randolph B DePrince

Jung K Lee

Thomas F Woiwode

Beatrice Ruhland-Fritsch

Palani Balu

Beatrice Ruhland

Sunila Piplani

Barbara McEowen Merrill

Sherril S Johnson

Randoph B DePrince

Inkyung Park

IL-7Rαγc ligands and IL-7Rαγc IgG-Fc fusion proteins are disclosed. The IL-7Rαγc ligands and IL-7Rαγc IgG-Fc fusion proteins are IL-7R agonists.

IL-7Rαγc ligand immunoglobulin fusion proteins

IL-7Rαγc binding compounds and pharmaceutical compositions comprising the IL-7Rαγc binding compounds are disclosed. IL-7Rαγc bonding compounds can act as IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.

IL-7R-α-γ binding compounds

IL-7R&#x3b1;&#x3b3;c binding compounds and pharmaceutical compositions comprising the IL-7R&#x3b1;&#x3b3;c binding compounds are disclosed. IL-7R&#x3b1;&#x3b3;c bonding compounds can act as IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.

IL-7R&#x3b1;&#x3b3;c binding compounds

IL-2R&#x3b2;&#x3b3;c binding compounds, and pharmaceutical compositions comprising the IL-2R&#x3b2;&#x3b3;c binding compounds are disclosed. IL-2R&#x3b2;&#x3b3;c binding compounds can act as IL-2R agonists and are useful in treating cancer, autoimmune diseases and inflammatory diseases.

IL-2R-&#x3b2;&#x3b3; binding compounds

Peptidyl IL-2R&#x3b1; ligands and compounds comprising the IL-2R&#x3b1; ligands are disclosed. The IL-2R&#x3b1; ligands and compounds such as synthetic monomers, homodimers, or heteromers and recombinant fusion proteins comprising the IL-2R&#x3b1; ligands can be used as targeting or imaging agents, as diagnostics or to treat cancers and autoimmune diseases.

IL-2alpha receptor subunit binding compounds

IL-2R&#x3b2; ligands and IL-2R&#x3b3;c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R&#x3b2; ligands and/or the IL-2R&#x3b3;c ligands can be IL-2 receptor agonists.

IL-2Rgamma binding compounds

IL-2RBETA binding compounds

IL-7R&#x3b1; ligands and compounds comprising IL-7R&#x3b1; ligands are disclosed. The IL-7R&#x3b1; binding compounds include fusion proteins comprising the IL-7R&#x3b1; ligands and can act as IL-7R agonists.

IL-7R-&#x3b1; binding compounds

Dual receptor binding compounds comprising IL-2R&#x3b2;, IL-7R&#x3b1;, and R&#x3b3;c ligands, and pharmaceutical compositions comprising the dual receptor binding compounds are disclosed. The dual receptor binding compounds can act as IL-2R and IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.

Dual IL-2R and IL-7R binding compounds

IL-2RBeta binding compounds

IL-2R&#x3b2;  ligands and IL-2R&#x3b3;c ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2R&#x3b2;  ligands and/or the IL-2R&#x3b3;c ligands can be IL-2 receptor agonists.

IL-2R&#x3b3; binding compounds

Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.

Peptides and compounds that bind to a receptor

Reagents and methods for detecting target proteins in a sample are provided. The reagents include a replicable genetic package, a protein displayed on an exterior surface of the package that is expressed from a heterologous nucleic acid borne by the package, and one or more antibodies complexed with the expressed protein and which have an open binding site for a target protein. Thus, a segment of the nucleic acid encodes for an epitope that is shared by the expressed polypeptide and the target protein. The reagents can be utilized individually or as part of a library or an array to bind target proteins within protein samples to form one or more complexes. By determining the sequence of the segment of the heterologous nucleic acid of a package within a complex, one can identify the target protein since the segment encodes for an epitope that is shared by the expressed and target proteins.

Epitope-captured antibody display

Peptides which bind to selected receptor molecules are identified by screening libraries which encode a random or controlled collection of amino acids. Peptides encoded by the libraries are expressed as fusion proteins of bacteriophage coat proteins, and bacteriophage particles are then screened against the receptors of interest. Peptides having a wide variety of uses, such as therapeutic or diagnostic reagents, may thus be identified without any prior information on the structure of the expected ligand or receptor molecule.

Peptide library and screening systems

Growing community of inventors

Menlo Park, CA, United States of America

Steven E Cwirla